CY1117593T1 - Ανταγωνιστης cgrp-υποδοχεα - Google Patents
Ανταγωνιστης cgrp-υποδοχεαInfo
- Publication number
- CY1117593T1 CY1117593T1 CY20161100254T CY161100254T CY1117593T1 CY 1117593 T1 CY1117593 T1 CY 1117593T1 CY 20161100254 T CY20161100254 T CY 20161100254T CY 161100254 T CY161100254 T CY 161100254T CY 1117593 T1 CY1117593 T1 CY 1117593T1
- Authority
- CY
- Cyprus
- Prior art keywords
- receptor
- cgrp
- disclosure
- compound
- shock
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 3- (7-methyl-1H-indazol-5-yl) -1 - (4- (1-methylpiperidin-4-yl) piperazin- 1-yl) -1-oxopropan-2-yl Chemical group 0.000 abstract 1
- 229940127597 CGRP antagonist Drugs 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η αποκάλυψη γενικά σχετίζεται με την ένωση του τύπου Ι, (R)-N-(3-(7-μεθυλο-1H-ινδαζολ-5-υλο)-1 -(4-( 1 -μεθυλοπιπεριδιν-4-υλο)πιπεραζιν-1 -υλο)-1 -οξοπροπαν-2-υλο)-4-(2-οξο-1,2-διυδροκινολιν-3-υλο)πιπεριδινο-1-καρβοξαμίδιο, συμπεριλαμβανομένων των φαρμακευτικά αποδεκτών αλάτων, η οποία είναι ανταγωνιστής του CGRP-υποδοχέα. Η αποκάλυψη επίσης σχετίζεται με φαρμακευτικές συνθέσεις και μεθόδους για χρήση της ένωσης στη θεραπευτική αγωγή διαταραχών σχετιζόμενων με CGRP, μεταξύ αυτών πονοκεφάλων ημικρανίας, νευρογενούς αγγειοδιαστολής, νευρογενούς φλεγμονής, θερμικής βλάβης, κυκλοφορικού σοκ, έξαψης σχετιζόμενης με εμμηνόπαυση, φλεγμονωδών παθήσεων αεραγωγών όπως άσθματος, χρόνιας αποφρακτικής πνευμονοπάθειας (COPD), και καρκίνου.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117593T1 true CY1117593T1 (el) | 2017-06-28 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100254T CY1117593T1 (el) | 2010-03-30 | 2016-03-24 | Ανταγωνιστης cgrp-υποδοχεα |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8481546B2 (el) |
| EP (1) | EP2552906B1 (el) |
| JP (1) | JP5908455B2 (el) |
| KR (3) | KR101854249B1 (el) |
| CN (1) | CN102834388B (el) |
| AR (1) | AR080746A1 (el) |
| AU (1) | AU2011233627B2 (el) |
| BR (1) | BR112012024785B1 (el) |
| CA (1) | CA2794950C (el) |
| CL (1) | CL2012002739A1 (el) |
| CY (1) | CY1117593T1 (el) |
| DK (1) | DK2552906T3 (el) |
| EA (1) | EA022815B1 (el) |
| ES (1) | ES2562610T3 (el) |
| HK (1) | HK1174914A1 (el) |
| HR (1) | HRP20160287T1 (el) |
| HU (1) | HUE028735T2 (el) |
| IL (1) | IL221665A (el) |
| MX (1) | MX2012010725A (el) |
| NZ (1) | NZ603231A (el) |
| PE (1) | PE20130340A1 (el) |
| PL (1) | PL2552906T3 (el) |
| PT (1) | PT2552906E (el) |
| RS (1) | RS54608B1 (el) |
| SG (1) | SG183918A1 (el) |
| SI (1) | SI2552906T1 (el) |
| SM (1) | SMT201600078B (el) |
| TW (1) | TWI483937B (el) |
| WO (1) | WO2011123232A1 (el) |
| ZA (1) | ZA201207292B (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| US12030868B2 (en) * | 2018-10-13 | 2024-07-09 | Pfizer Ireland Pharmaceuticals | Prodrugs of CGRP antagonists |
| EP3911409A4 (en) * | 2019-01-20 | 2022-10-19 | Biohaven Pharmaceutical Holding Company Ltd. | CGRP ANTAGONISTS FOR TREATMENT OF BREAKTHROUGHT MIGRAINE |
| EP3952899A1 (en) | 2019-04-11 | 2022-02-16 | R.P. Scherer Technologies, LLC | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
| JP2023507094A (ja) * | 2019-12-17 | 2023-02-21 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | Ｃｇｒｐ阻害剤の鼻腔内医薬組成物 |
| KR20230088442A (ko) * | 2020-11-19 | 2023-06-19 | 화이자 아일랜드 파마슈티컬즈 | Cgrp 억제제의 개선된 전달을 위한 조성물 |
| KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
| WO2022217008A1 (en) | 2021-04-09 | 2022-10-13 | Teva Czech Industries S.R.O | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| WO2024100599A1 (en) | 2022-11-09 | 2024-05-16 | Teva Czech Industries S.R.O. | Solid state forms of zavegepant hydrochloride and process for preparation thereof |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487976C (en) * | 2002-06-05 | 2011-07-26 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| CN101495480B (zh) * | 2006-05-03 | 2013-07-10 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active IP Right Grant
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Application Discontinuation
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en active Application Filing
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active IP Right Grant
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 RS RS20160164A patent/RS54608B1/en unknown
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
-
2013
- 2013-02-19 HK HK13102079.5A patent/HK1174914A1/zh unknown
-
2016
- 2016-03-21 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2016-03-21 SM SM201600078T patent/SMT201600078B/xx unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117593T1 (el) | Ανταγωνιστης cgrp-υποδοχεα | |
| TN2012000139A1 (en) | Cgrp receptor antagonists | |
| WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
| CY1122121T1 (el) | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας | |
| CY1121248T1 (el) | Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| EA200901514A1 (ru) | Новая сольватная и кристаллическая форма производных карбамоилциклогексана | |
| NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| NO20064888L (no) | Heterocykliske CGRP antagonister for behandling av migrene | |
| JP2015501799A5 (el) | ||
| TN2014000033A1 (fr) | Indazoles | |
| UA111725C2 (uk) | Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол | |
| AR093017A1 (es) | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO | |
| ECSP077398A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
| RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
| EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины | |
| JP2017500321A5 (el) | ||
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| NZ600266A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| NZ595797A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| NZ608729A (en) | 1,2,4-triazolone derivative | |
| JPWO2021170109A5 (el) | ||
| SG11201604517WA (en) | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof |